fig2
Figure 2. The development landscape of clinical trials related to PD-1/PD-L1 inhibitors. (A) Number of clinical trials involving PD-1/PD-L1 inhibitors across different phases; (B) Distribution of cancer types in clinical trials related to anti-PD-1 therapy; (C) Distribution of cancer types in clinical trials related to anti-PD-L1 therapy. Data from ClinicalTrials.gov. PD-1: Programmed death-1; PD-L1: programmed death-ligand 1; NA: not applicable.
